Chemistry:CVT-301
From HandWiki
CVT-301 is an inhaled form of levodopa for the treatment of Parkinson's disease. It was developed by Civitas Therapeutics. A phase III clinical trial was completed in 2016.[1] A New Drug Application filed with the FDA in 2017[2] was rejected in a refuse-to-file letter.[3]
References
- ↑ "Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes - Full Text View - ClinicalTrials.gov" (in en). https://clinicaltrials.gov/ct2/show/NCT02240030.
- ↑ "CVT-301 for Treatment of Parkinson's Disease OFF Episodes | Acorda.com" (in en). http://www.acorda.com/products/research-development/cvt-301.
- ↑ "Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report" (in en-US). https://endpts.com/biogen-ucb-step-up-to-kick-the-tires-at-acorda-as-buyout-buzz-grows-report/.
 |
